Market access of biosimilars: Not only a cost issue

Oncologie

Volumn 13, Issue 5, 2011, Pages 218-221

  Simoens, S ^a   Verbeken, G ^a,b   Huys, I ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

Biopharmaceutical; Biosimilar; Pricing; Registration; Reimbursement

Indexed keywords

ANTINEOPLASTIC AGENT; BIOSIMILAR DRUG; UNCLASSIFIED DRUG;

CHEMICAL COMPOSITION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; REGISTRATION; REIMBURSEMENT; REVIEW; TOXICOLOGICAL PARAMETERS;

EID: 79959647129     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-011-2018-8     Document Type: Review

References (19)

1. K. de Joncheere A. Rietveld C. Huttin 2002 Experiences with generics Int J Risk Safety Med 15 101 109 (Pubitemid 36398733)
2. P.J. Declerck F. Darendeliler M. Goth, et al. 2010 Biosimilars: controversies as illustrated by rhGH Curr Med Res Opin 26 1219 1229 20302553 10.1185/03007991003719642 1:CAS:528:DC%2BC3cXkslOisro%3D
3. European Generic Medicines Association (2010) EGA handbook on biosimilar medicines. European Generic Medicines Association, Brussels
4. European Medicines Agency (2006) Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin. European Medicines Agency, London
5. European Medicines Agency (2006) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. European Medicines Agency, London
6. H. Grabowski I. Cockburn G. Long 2006 The market for follow-on biologics: how will it evolve? Health Aff 25 1291 1301 10.1377/hlthaff.25.5.1291 (Pubitemid 44497628)
7. D.A. Hughes 2010 Biosimilars: evidential standards for health technology assessment Clin Pharmacol Ther 87 257 261 20160743 10.1038/clpt.2009.112 1:STN:280:DC%2BC3c7ht1GmsQ%3D%3D
8. D.R. King P. Kanavos 2002 Encouraging the use of generic medicines: implications for transition economies Croat Med J 43 462 469 12187525 (Pubitemid 34976432)
9. Long M, Trout J, Akpinar P (2009) Biosimilars: HGH to TNFS, how will payers respond? ISPOR 12th Annual European Congress, Paris
10. H. Mellstedt 2010 The future of biosimilars Hosp Pharm Eur 49 33 34
11. Oldham T (2006) Strategies for entering the biosimilar market. In: Oldham T (ed) Biosimilars-evolution or revolution? Biopharm Knowledge Publishing, London
12. S.D. Roger 2010 Biosimilars: current status and future directions Expert Opin Biol Ther 10 1011 1018 20384525 10.1517/14712591003796553 1:CAS:528:DC%2BC3cXnt1ykurs%3D
13. H. Schellekens 2009 Biosimilar therapeutics-what do we need to consider? NDT Plus 2 i27 i36 19461855 10.1093/ndtplus/sfn177 1:CAS:528: DC%2BD1MXit1Cht7o%3D
14. Scottish Medicines Consortium (2010) Epoetin zeta. Scottish Medicines Consortium, Edinburgh
15. S. Siena M.J. Piccart F.A. Holmes, et al. 2003 A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer Oncol Rep 10 715 724 12684649 1:CAS:528:DC%2BD3sXjsVOltLk%3D
16. A. Stewart P. Aubrey J. Belsey 2010 Addressing the health technology assessment of biosimilar pharmaceuticals Curr Med Res Opin 26 2119 2126 20649394 10.1185/03007995.2010.505137 1:CAS:528:DC%2BC3cXhtVWqu7fI
17. The consolidated Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use as amended by Directive 2002/98/EC, Directive 2004/24/EC and Directive 2004/27/EC
18. Title VII of the Patient Protection and Affordable Care Act of 2010, Improving Access to Innovative Medical Therapies-Subtitle (Biologics Price Competition and Innovation Act of 2009, section 351(k), 351 (l), 351(m). Pub.L.No.111-48. 2011. 3-2-2011
19. L. Zuniga B. Calvo 2010 Biosimilars approval process Regul Toxicol Pharmacol 56 374 377 19925842 10.1016/j.yrtph.2009.11.004